HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NPD in Europe

This article was originally published in The Rose Sheet

Executive Summary

NPD Group has entered into a non-binding letter of intent with TNS Infratest to acquire its Italian perfumery business, company announces Oct. 12. TNS Infratest is an Italian subsidiary of international market information provider Taylor Nelson Sofres. Deal aims to "strengthen NPD's position as the leading provider of comprehensive sales tracking information for the Selective Beauty industry in Europe and the U.S.," according to NPD. "This is an exciting step forward and paves the way for future expansion of our Selective Beauty business in Europe and Asia," NPD Europe President Andy Tarshis notes...

You may also be interested in...



NPD Beauty

Claude Charbit is appointed to newly created position of president, Global Beauty, effective Nov. 1, consumer and retail information company reports Oct. 24. Charbit has been serving as a special adviser to NPD regarding its European Beauty business since July 2003 and recently led NPD negotiations with TNS Infratest to acquire its Italian perfumery business (1"The Rose Sheet" Oct 17. 2005, In Brief). Exec has held positions at Information Resources Inc, SOFRES, EuroRSCG Group and AC Nielsen. Charbit will report to NPD Europe President Andy Tarshis. His experience will be "invaluable" in "continuing to grow our beauty business, leveraging our current position as market leader in France and Italy for continued growth in Europe and beyond," Tarshis said...

Medicare Retail Drug Spending Accelerates In 2018 Despite Price Declines

Prices for retail drugs across US payers decreased for the first time in years, driven by a drop in generic prices and “little to no growth” in prices for brands.

Pfizer's Bourla: "I Think We Forgot What It Looks Like To Grow"

The big pharma CEO reflected on his first year of leadership at Pfizer during the Forbes Healthcare Summit and talked about executing on a plan to deliver 6% growth through 2026. 
UsernamePublicRestriction

Register

RS013439

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel